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Regulator of G protein–signaling (RGS) proteins are a family of more than 30 intracellular proteins that negatively
modulate intracellular signaling of receptors in the G protein-coupled receptor family. This family includes receptors
for opioids, cannabinoids, and dopamine that mediate the acute effects of addictive drugs or behaviors and chronic
effects leading to the development of addictive disease. Members of the RGS protein family, by negatively modulating
receptor signaling, influence the intracellular processes that lead to addiction. In turn, addictive drugs control the
expression levels of several RGS proteins. This review will consider the distribution and mechanisms of action of
RGS proteins, particularly the R4 and R7 families that have been implicated in the actions of addictive drugs, how
knowledge of these proteins is contributing to an understanding of addictive processes, and whether specific RGS
proteins could provide targets for the development of medications to manage and/or treat addiction.
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Introduction
Regulator of G protein–signaling (RGS) proteins
are a family of more than 30 intracellular proteins
that negatively modulate signaling pathways of G
protein-coupled receptors (GPCRs).1–4 GPCRs are
a large family of plasma membrane receptors for en-
dogenous neurotransmitters that couple to intracel-
lular heterotrimeric GTP binding proteins (G pro-
teins) comprising an  subunit and a heterodimer
of  subunits, which activate signaling cascades
within the cell. GPCRs are responsible for the ac-
tions of many different addictive substances either
as direct targets or as a secondary consequence of
the action of the addictive agent. These receptors
and their cognate signaling pathways not only me-
diate acute effects of addictive drugs/behaviors but
are also vital to the development of the addictive
disease whether this be addiction to legal (alcohol,
nicotine) or illegal (amphetamine, cocaine, heroin,
cannabis) drugs, substances (solvents), or behav-
ioral addictions (gambling). Because RGS proteins
modulate GPCR signaling, they are important com-
ponents in the control of intracellular events that
drive the addictive process. Indeed, the interaction
between addictive drugs and RGS proteins appears
to be interdependent because there is considerable
evidence that RGS proteins are in turn manipu-
lated by the addictive process.5 Although it can be
hypothesized that RGS proteins play a role in all
addictions, published literature to date has concen-
trated on the stimulants amphetamine and cocaine
and the opioid morphine.
RGS protein modulation of G protein
signaling
Members of the GPCR family of receptors include
the opioid receptors, especially the -opioid recep-
tor as the primary target for heroin and prescrip-
tion opioids, the cannabinoid CB1 receptors, the
dopamine D1 and D2 families of receptors that are
the mediators of reward or the anticipation of re-
ward for many addictions6,7 as well as metabotropic
glutamate receptors that may regulate many behav-
ioral actions of addictive drugs.8
GPCRs show specificity for coupling to a par-
ticular type of G protein. G proteins are
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Figure 1. G protein cycle. In the resting state the seven-
transmembrane domain receptor is associated with the
G heterotrimeric G protein with the G subunit
bound to GDP. Activation of the receptor promotes the
exchange of GDP for GTP on the G subunit. This
leads to separation of the G and G subunits and
allows them to interact with downstream effectors, such
as adenylyl cyclase (AC) and ion channels. The pool of
active G–GTP is slowly hydrolyzed by the GTPase ac-
tivity of the G subunit. This process is accelerated by
the GAP activity of RGS proteins. The inactive G–GDP
has high affinity for the G subunits, the heterotrimer
is reformed, and the cycle can start again. By reducing the
lifetime of the active G–GTP, RGS proteins also reduce
the accumulation of the G subunits and so negatively
modulate all branches of G protein–mediated signaling.
divided into four broad families: Gs activates the
enzyme adenylyl cyclase leading to an increase in
cAMP in the cell, the Gi/o family inhibits adeny-
lyl cyclase, the Gq family activates the enzyme
phospholipase C, leading to the release of cal-
cium from intracellular stores, and G12/13 regu-
lates cell growth and differentiation. The associated
 subunits also interact with a variety of intracel-
lular effectors including inwardly rectifying potas-
sium channels, calcium channels, phospholipase C,
and the mitogen-activated protein kinase pathway.
Dopamine D1 receptors primarily couple to Gs,
the opioid, cannabinoid, dopamine D2 receptors,
and metabotropic glutamate receptors 2 and 3 pre-
dominantly couple to Gi/o proteins. In the resting
state, the G of the heterotrimer G protein binds the
guanine nucleotide GDP. Occupation of a GPCR by
endogenous neurotransmitters or exogenous ago-
nists activates the receptor, triggering the exchange
of GDP for GTP on the G subunit and separation
from the  subunits. Both G–GTP and  acti-
vate downstream effectors. Hydrolysis of the bound
GTP by the GTPase activity of the  subunit pro-
vides G–GDP, which re-associates with the  het-
erodimers thus terminating the signal. RGS proteins
bind to the GTP-bound G subunit and accelerate
the rate of hydrolysis of GTP (Fig. 1).
RGS proteins are characterized by the presence of
a consensus 125 amino-acid sequence, the so-called
RGS box or RH homology domain (Fig. 2), which
binds G–GTP proteins1–4,9 and functions as a GAP
(GTPase-accelerating protein). Gi/o and Gq sub-
types of G proteins are sensitive to this GAP activity
due to their relatively slow endogenous rate of GTP
hydrolysis. In contrast, Gs, which already hydroly-
ses GTP rapidly, is insensitive to GAP activity. GAP
action at GTP-bound Gi/o- or Gq-coupled re-
ceptors leads to a more rapid return to the inactive
G–GDP state and a faster recombination of the
G and  signaling molecules. By reducing the
lifetime of G–GTP and  molecules, RGS pro-
teins limit G protein signal strength at steady state
and thus act as negative modulators of G protein sig-
naling. As a result, RGS proteins exhibit profound
control over both the potency and efficacy of ago-
nist action. For example, in an in vitro system com-
pletely lacking RGS activity at Go, the efficacy of
morphine is increased several-fold and the potency
40-fold converting morphine from a partial agonist
to a robust full agonist.10
RGS protein families
Many proteins with RH domains have been identi-
fied. These proteins have been divided into various
families (Table 1) on the basis of similarity in amino
acid composition.2,4 Members of the R4 and RZ
families are smaller proteins consisting largely of
Figure 2. Cartoon of R4- and R7-type RGS proteins
bound to G . Family R4 (e.g., RGS4) is essentially an
RGS domain plus an N-terminal helical domain. The
more complex R7 family (e.g., RGS9-2) contains protein–
protein binding domains to allow association with other
proteins, including the obligate partners R7 binding pro-
tein (R7BP) and G5. For other abbreviations see Table 1.
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Table 1. Families of RGS proteinsa
Family Members Structure: RGS domain plus
RZ RGS17, 19, 20b N-terminal cysteine string
R4 RGS1, 2 , 3,c 4, 5, 8, 13, 16, 18, 21 N-terminal amphipathic helix
R7 RGS6, 7, 9, 11 GGL + DEP + R7H domains
R12 RGS10, 12, 14 Variable—can contain PDZ
RBD, and GoLoco domains
RA Axin, Conductin GSK + CAT + PP2A + DIX
RL P115RhoGEF DH + PH
RL GRK2 and 3 Ser/Thr kinase + PH
aCAT, -catenin binding site; DEP, disheveled, EGL-10, pleckstrin homology domain; DH, Dbl-homology (RhoGEF)
domain; GEF, guanine–nucleotide exchange factor; GGL, G protein -like domain; GoLoco, Gi/o–GDP binding
motif; GRK, G protein receptor kinase; GSK, glycogen synthase kinase 3-binding domain; PDZ, PSD95/Dlg/Z0-1
domain; PH, pleckstrin homology domain; R7H, R7 homology domain; PP2A, protein phosphatase 2A homology
region; RBD, Rap1/2-binding domain; DIX, dimerization domain.
bRGS17 and 20 are also known as RGSZ2 and RGSZ1, respectively; RGS20 is also known as GAIP (G-interacting
protein).
cRGS3 is much larger than other members of the R4 family and has multiple splice variants, some of which include a
PDZ domain.
the RGS domain (Fig. 2). Other families have much
more complex structures with domains that allow
for protein–protein interactions. Particularly perti-
nent to addiction is RGS9-2 (Fig. 2), a member of
the R7 family, which, in addition to the conserved
RGS box, contains several other domains/motifs.
R7 family members possess a DEP (disheveled, Egl-
10, pleckstrin) domain that binds the adapter pro-
tein R7BP,11,12 which promotes membrane associa-
tion13,14 and stabilizes RGS9-2 against degradation.
The R7 family members also have a GGL (G gamma
like) domain that allows binding to the G protein
5 subunit (G5),15 which further promotes pro-
tein stability.16 RGS proteins may also be regulated
by phosphorylation17,18 and lipid modification.19
Strongly acidic lipids, such as phosphatidyl inositol
trisphosphate (PIP3) and phosphatidic acid, tran-
siently bind to and inhibit the GAP activity of R4
family members; an inhibition that can be reversed
by calcium/calmodulin.20,21
In addition to RGS proteins that act as GAPs, there
are other proteins with RH domains that bind to G
but do not necessarily exhibit GAP activity. The RH
domain of GPCR kinases (GRKs) that are recruited
by  subunits for receptor phosphorylation binds
to Gq and inhibits its ability to activate phospho-
lipase C.22 The Rho guanine nucleotide exchange
factors (RhoGEFs) bind to the G proteins G12 and
G1323 and also interact with Gq.24 The primary
function of the RH domain in the RH-RhoGEF pro-
teins is to link the GPCR to Rho-mediated signaling
pathways that control many cell processes includ-
ing the actin cytoskeleton, cell growth, prolifera-
tion, and differentiation.25 The proteins axin and
conductin regulate the Wnt signaling pathway im-
portant for embryogenesis and cancer.
Although many RGS proteins are GAPs for all
members of the Gi/o and Gq families, some ex-
hibit selectivity. For example members of the R7
family, which includes RGS9-2, are selective for
Go,26,27 whereas RGS2 is considered to be more
effective as a GAP at Gq.28 There is also increas-
ing evidence that specificity for RGS proteins can be
conferred by the GPCR.29–32 Several RGS proteins,
including RGS2, 4, 8, and 9, have been shown to act
as GAPs to modulate -opioid receptor signaling in
vitro, but there may be specificity under endogenous
conditions.33 However, the distribution of RGS pro-
tein types relative to receptor and G subtype distri-
bution may be the most important facet governing
selectivity.5
Distribution of RGS proteins
mRNA for the various members of the RGS pro-
tein family is unevenly distributed across the central
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nervous system. In particular, there is specific local-
ization of certain RGS proteins in regions implicated
in the action of addictive drugs. RGS2 mRNA is
found in the periform and neocortex, caudate puta-
men, amygdala, hippocampus, and locus coeruleus
(LC).34,35 RGS4 mRNA is found in high levels in the
thalamus, caudate putamen, and nucleus accum-
bens (NAcc), as well as the prefrontal cortex,36,37
where incorrect dopamine and serotonin function
may be responsible for some of the symptoms of
schizophrenia. Indeed, RGS4 has been suggested as a
susceptibility gene for schizophrenia38,39 and RGS4
protein is reduced in the prefrontal cortex of hu-
man schizophrenic post mortem brains40 and in a
rat model of schizophrenia.41
RGS9 is found in two forms: a short form (RGS9-
1) that is exclusive to the retina, where it acts as
a GAP for the retinal G protein Gt, and a longer
form (RGS9-2) that is largely confined to striatal
regions in rodent and human brain, that is, the cau-
date putamen, NAcc, islands of Calleja, and olfac-
tory tubercle.36,42–44 This distribution mimics that
of striatal specific proteins, such as dopamine D1
receptors, adenylyl cyclase type V, and the phospho-
protein DARPP-32 (dopamine and cyclic adeno-
sine 3′,5′-monophosphate regulated phosphopro-
tein with molecular mass of 32 kDa).45 In addition,
RGS9-2 is expressed at lower levels in regions asso-
ciated with the antinociceptive actions of morphine,
namely the periaqueductal gray (PAG) and the dor-
sal horn of the spinal cord.46
Interactions between RGS proteins
and drugs of abuse
The localization of RGS2 and 4 and in particu-
lar RGS9-2 led to speculation of a role in addic-
tive processes. This idea is strengthened by sev-
eral reports showing that addictive substances cause
changes in the levels of RGS proteins or RGS mRNA,
suggesting a role for these drug-induced modi-
fications in the addictive process. Several studies
have addressed changes in RGS after drug exposure
but there have been fewer studies on the roles of
RGS proteins in modulating responses to addictive
drugs.
RGS2
The mRNA for RGS2 has a short half-life,47 and
the RGS2 protein itself is targeted for proteasomal
degradation,48 suggesting that RGS2 protein lev-
els are tightly regulated. Although no studies to
date have demonstrated changes in RGS2 protein
in response to addictive drugs, there is evidence
for alterations at the mRNA level. In the rat, ad-
ministration of amphetamine, methamphetamine,
or cocaine rapidly upregulates RGS2 mRNA levels
in the striatum47 on a rapid time scale similar to
the induction of c-Fos expression.49 Moreover, the
upregulation is transient and persists with repeated
drug administration,50 indicating that RGS2 may
be involved in the acute actions of amphetamine.
Also, because rapid alterations in RGS2 mRNA lev-
els occur repeatedly with each amphetamine ad-
ministration, RGS2 may function as a modulator
for neuroadaptive changes that lead to dependence
and sensitization.50
Increases in synaptic dopamine after adminis-
tration of stimulants probably underlie the rapid
changes in RGS2. Both the rat and human gene
for RGS2 contain cAMP-sensitive elements51,52 (the
human gene has a CRE51) and so dopamine stim-
ulation of adenylyl cyclase via Gs-coupled D1
receptors will lead to an increase in RGS2 mes-
sage. Indeed, dopamine D1 antagonists prevent
the amphetamine-induced upregulation of RGS2
mRNA.53 Conversely, activation of the Gi/o-
coupled D2 receptor inhibits adenylyl cyclase, lead-
ing to decreased RGS2 mRNA expression, whereas
D2 antagonists, such as haloperidol, stimulate RGS2
mRNA expression and show an additive effect with
amphetamine.47,53
The rapid and selective upregulation of RGS2
mRNA in response to stimulants indicates a role
for RGS2 in the control of dopamine-mediated sig-
naling events. Although RGS2 preferentially acts at
Gq it can also act as a GAP to regulate Go.54 Con-
sequently, increased levels of RGS2 would probably
reduce D2 receptor signaling by this GAP activity.
Yet, there is no similar GAP activity at the Gs-
coupled dopamine D1 receptor. Therefore, the abil-
ity of RGS2 to modulate D2 but not D1 signaling
could explain the altered balance between D1 and
D2 signaling that is thought to underlie adaptive
processes to chronic cocaine. On the other hand,
RGS2 as well as several other RGS proteins (RGS3,
4, 10, and 13) directly inhibit adenylyl cyclases 2,
5, and 6.55,56 The mechanism behind this effect is
unknown but could be due to a direct interaction
of RGS2 with Gs, leading to GAP-independent
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inhibition, and/or a direct interaction with the
adenylyl cyclase enzyme.57 Thus, although RGS2
does not directly modulate D1 receptor signaling
by acting as a GAP, it might negatively regulate D1
receptor signaling to adenylyl cyclase.
The rapid control of RGS2 expression by stim-
ulants provides a potential feedback mechanism to
finely tune dopaminergic signaling. By acting at an
early stage of the signaling cascade, RGS2 can in-
hibit multiple branches of the D2 receptor signaling
cascade as well as D1 receptor signaling to adenylyl
cyclase and its downstream effects. In cases where
both receptors are coexpressed on the same neuron
there is the potential for cross-talk. Consequently,
RGS2 can regulate many dopamine-induced behav-
iors associated with drugs of abuse.
Chronic morphine, acting at Gi/o-coupled -
opioid receptors to inhibit adenylyl cyclase, has been
reported to reduce RGS2 mRNA in dopaminergic
neurons in the ventral tegmental area (VTA) of
mice.58 In contrast, precipitation of opioid with-
drawal leads to a modest increase in RGS2 mes-
sage in the LC.59 Chronic administration of the
“date rape” drug GHB (-hydroxybutyrate), act-
ing at GABAB receptors similarly reduces RGS2
mRNA expression in the VTA,58 a region wherein
GABAB receptor coupling to inwardly rectifying
potassium channels is sensitive to modulation by
RGS2. Therefore, the GHB-induced reduction in
RGS2 mRNA might provide positive feedback to
enhance GABA coupling efficiency and increase the
potency of GHB to inhibit dopamine firing rates. In-
deed, GHB-induced decreases in RGS2 mRNA are
accompanied by a loss of drinking preference for
GHB.58
RGS4
RGS4 is also an unstable protein that is subjected to
N-end rule degradation48,60 and is regulated by tran-
scription and RNA stabilization.61 Addictive drugs
generally lead to increased RGS4 mRNA expression,
although the effects are not as marked as with RGS2
or as consistent,53,59,62–64 which may be due to re-
gion and temporally specific changes. In the severely
morphine-dependent mouse there is a downregula-
tion of RGS4 mRNA in the lateral hypothalamus.64
In the rat, RGS4 protein is upregulated in the NAcc
after acute morphine but downregulated in the LC,63
where RGS4 protein is expressed mainly in nora-
drenergic (tyrosine hydroxylase positive) neurons.59
In contrast, treatment of rats with high levels of mor-
phine for several days led to a twofold increase in the
level of RGS4 protein in the LC, but with no change
in the mRNA for RGS4.59 The increased protein ex-
pression returned to baseline after precipitation of
withdrawal with the opioid antagonist naloxone, ac-
companied by a threefold increase in RGS4 message.
A plausible rationale for this seeming mismatch be-
tween RNA and protein is that the protein is sta-
bilized in the presence of chronic morphine such
that withdrawal of morphine leads to increase pro-
teolytic breakdown, as a consequence of which the
level of mRNA is increased.59 Although large doses
of morphine and naloxone were used in these stud-
ies, no changes were observed in the expression of
several other RGS proteins and no changes in RGS4
protein or message were observed in the PAG, an
area important for morphine antinociception. On
the other hand, RGS4 mRNA was decreased in the
occipital lobe after precipitated withdrawal, an effect
that was attributed to withdrawal-induced increases
in noradrenergic signaling at Gs-coupled stimula-
tory -adrenergic receptors.59
In vitro, RGS4 negatively modulates signaling at
opioid receptors by acting as a GAP.59,65 Therefore,
the increased RGS4 seen in the LC after chronic mor-
phine exposure will reduce Gi/o-mediated signaling
further and so contribute to tolerance development.
However, there are conflicting reports from stud-
ies using RGS4-knockout mice of the importance of
RGS4. A study of RGS4-knockout mice has reported
no morphine phenotype,66 which might indicate
that other RGS proteins are functionally redundant
with RGS4. In contrast, a study with an indepen-
dent strain of mice has reported increased reward
and more severe withdrawal symptoms.67
The response of RGS4 mRNA levels to stimulants
has been various and assay dependent.50,54,63,68–71
Yuferov et al.69 reported a decrease in RGS4 mRNA
in the caudate putamen of Fisher rats after 3 days
of binge cocaine. Similarly, Schwendt et al.71 report
a decrease in RGS4 mRNA expression in the pre-
frontal cortex and dorsolateral striatum 21 days af-
ter abstinence from cocaine either self-administered
or by noncontingent binge pattern administration.
Strikingly, exposure of the rats to the cocaine-
associated environment caused a return of RGS4
to normal levels, indicating a role for RGS4 in the
long-term actions of cocaine.
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Dopamine receptor agonists control RGS4
mRNA levels in a manner that is opposite to that
of RGS2.53,68 Dopamine D1 agonists decrease RGS4
gene expression and D2 agonists increase RGS4
gene expression. Consequently, observed changes
in RGS4 may result from the altered balance of
dopamine receptor functioning that occurs after
prolonged cocaine where there is an increase in
D1 function and a decrease in D2 function. Alter-
natively, blockade of N-methyl-d-aspartate recep-
tors decreases RGS4 mRNA,72 suggesting a role for
the cocaine-induced downregulation of N-methyl-
d-aspartate receptor subunits. With the potential
negative modulation by RGS4 of Gi/o-coupled D2
receptors, the reduction in RGS4 may contribute
to resetting the balance of dopamine D2 and D1
signaling.
RGS9-2
Changes in RGS9-2 protein levels after morphine
have been reported, but the direction is temporally
dependent. Two hours after acute morphine, RGS9-
2 protein levels increase by 50% in the caudate puta-
men and NAcc of mice, along with regions involved
in the antinociceptive actions of morphine, namely,
the PAG and dorsal horn of spinal cord.46,73 In con-
trast, chronic exposure to morphine reverses this
rise and ultimately leads to a 50% reduction in basal
RGS9-2 protein levels. No changes in the levels of
the binding partner G5 were observed.73
These dynamic changes in RGS9-2 protein seen
after morphine administration are not accompanied
by alterations in mRNA levels. Therefore, morphine
treatment might alter the protein itself, as appears
to occur with the smaller R4 family members. This
may result from the complex structure of RGS9-2
and its requirement for binding partners, such as
G5 and R7BP, which confer protein stability and
localization as well as promote proper folding of
RGS9-2.13–16 Interruption or stabilization of these
protein binding and folding processes could lead to
mRNA-independent changes in RGS9-2 levels. For
example, members of the R7 family have a conserved
Pro–Glu–Ser–Thr (PEST) sequence in the GGL do-
main, a signal for protein degradation that may be
hidden by the binding of G5.74
The physiological roles of RGS9-2 protein in the
actions of abused drugs have been inferred from
studies using targeted gene deletion or antisense
oligonucleotides to knock out/knock down RGS9-2
in rodents. RGS9-knockout mice showed more po-
tent responses to morphine related to their abuse
potential and other pharmacologies.46 For exam-
ple, in the conditioned place preference assay mice
are trained to associate administration of drug with
a particular environment as an indication of re-
ward. In this assay morphine is “rewarding” at
low doses, although this effect is reversed at higher
doses. RGS9-null mice show an approximately 10-
fold higher potency of morphine in this assay than
littermate wild-type controls. The increased potency
of morphine is reversed by restoration of RGS9-2
protein levels by injection of virus expressing RGS
directly into the in the NAcc.46 In contrast, overex-
pression of RGS4 has no effect, suggesting a selec-
tivity of RGS9-2. Because both RGS9-2 and RGS4
readily act as GAPs for Go, this selectivity is likely
to be achieved by the correct targeting of the more
complex RGS9-2 to the -opioid receptor.
In mice null for RGS946 or where RGS9 has been
knocked down by antisense treatment,75,76 there
is an increase in morphine-mediated antinocicep-
tion and a delay in the development of antinoci-
ceptive tolerance. Similarly, knockdown of the R7
family binding partner G5 enhances the antinoci-
ceptive response to the -opioid receptor ago-
nist DAMGO and inhibits acute tolerance.76 These
findings suggest that endogenous RGS9-2 inhibits
-opioid–mediated antinociception. Thus, the in-
crease in RGS9-2 expression after acute morphine
might enhance this negative modulation and so con-
tribute to the loss of effect, that is, tolerance. On
the other hand, antisense knockdown of RGS9 and
G5 facilitates tolerance to more sustained mor-
phine exposure.75,76 The reduction in RGS9-2 af-
ter chronic morphine will therefore act to maintain
antinociception as tolerance develops, although this
could incur the cost of increased dependence. In-
deed, compared to wild-type mice, RGS9-knockout
mice show a significant increase in behaviors as-
sociated with withdrawal including jumping, wet-
dog shakes, paw tremor, diarrhea, and ptosis, as
well as an increased in c-Fos expression in the
LC.46 It appears from studies to date that RGS9-
2 modulates all morphine pharmacology without
selectivity.
In contrast to chronic morphine, chronic co-
caine has been reported to cause relatively small in-
creases in RGS9-2 protein in the NAcc and caudate
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putamen, particularly in animals that self-
administered the drug.77 As observed with mor-
phine there was no change at the mRNA level. In
contrast, acute amphetamine has been reported to
reduce RGS9 mRNA expression in the dorsal stria-
tum of male rats,47 although a second study using di-
rect D1 and D2 agonists showed no effect.53 Despite
these small changes RGS9-2 does appear to be im-
portant for modulating dopamine signaling in stri-
atal regions. RGS9-2 is expressed in dopamine D2
expressing neurons in the NAcc44 and acts as a GAP
only for Go, which is almost exclusively respon-
sible for D2 receptor signaling.78 Moreover, mice
lacking RGS9 show a dopaminergic-mediated dysk-
inesia,79 and MTPT (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine)-treated monkeys show a
dyskinesia that is significantly reduced by viral ex-
pression of RGS9 in the dorsal striatum.80 Also,
monkeys overexpressing RGS9 exhibit a reduced
susceptibility to l-dopa–induced dyskinesias.80
As a consequence of loss of negative modula-
tion of D2 signaling, RGS9-knockout mice demon-
strate increases in cocaine-induced locomotor ac-
tivity, which can be prevented by overexpression of
RGS9-2 in the NAcc.74 In addition, these mice show
a potentiated locomotor sensitization on repeated
cocaine administration; sensitization of stimulant-
mediated behaviors is considered a major compo-
nent of drug-seeking behavior. The rewarding effect
of cocaine (as measured by place preference) is also
increased, although the effect is not as profound as
with morphine.
Exposure of ovariectomized female rats to estro-
gen for 2 weeks has been reported to cause a 30%
decrease in the level of mRNA for RGS9 in the shell of
the NAcc.81 A resulting reduction in RGS9-2 protein
should lead to increased signaling at Gi/o-coupled
receptors. Such a mechanism might explain the in-
crease in dopamine function caused by estrogen and
consequently may contribute to the increased vul-
nerability to the reinforcing effects of drugs of abuse
seen in females.82
Other RGS proteins
There are isolated reports linking RGS proteins
other than RGS2, 4, and 9 to abused drugs. Several
of these results are from microarray analysis profil-
ing after alcohol or nicotine in addition to changes
induced by opioids or stimulants.
R4 family
RGS3 and RGS5 are upregulated after amphetamine
in the striatum of the rat, although this requires
more sustained stimulation than required to up-
regulate RGS2.47 However, as with RGS2, upreg-
ulation of RGS3, but not RGS5, persists with re-
peated amphetamine administration.50 A reduction
in RGS13 has been reported in the prefrontal cor-
tex, NAcc, VTA, and amygdala of rats given chronic
nicotine.83 Nicotine challenge after intermittent ex-
posure and withdrawal resulted in decreased ex-
pression of RGS16 in several mouse strains but an
increase in a quasi-congenic RQI (recombinant
quantitative trait loci introgression) strain.84
R7 family
A small increase in RGS7 protein, after acute, but
not chronic, morphine is seen in the LC.59 As with
knockdown of RGS9, antisense knockdown of other
R7 family members RGS6, 7, or 11 gives an increase
in morphine-mediated antinociception and a delay
in the development of antinociceptive tolerance.76
In the C3H/HeJ mouse, but not the C57/BL6 mouse,
there is a significant regulation of RGS11 in the
amygdala and hippocampus in response to chronic
nicotine.85
RZ family
RGS20 has been shown to modulate -opioid re-
ceptor signaling in vitro,86 and antisense studies
have demonstrated that both RGS19 and RGS20
enhance morphine antinociception in the mouse.87
Withdrawal from chronic ethanol in mice showed
a downregulation of RGS19-interacting protein, a
protein that binds to both RGS19 and G and tar-
gets G for degradation.88
RGS proteins as potential targets for the
treatment of addictive diseases
Levels of several RGS proteins are manipulated
by addictive drugs, and experiments with knock-
down/knockout of RGS proteins show that several of
these proteins modulate signaling pathways down-
stream of GPCRs involved in addiction and sub-
sequent behaviors. With the fine-tuning that this
interdependency can evoke, it is possible to envis-
age RGS proteins might be targets for drug abuse
treatment. Obviously the study of the role of RGS
proteins in addiction would benefit from the
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development of small-molecule inhibitors of RGS
proteins. This research is still in its infancy, although
there are indications for interaction sites at the
RGS–G interface that could be specific for partic-
ular RGS–G combinations89 and that compounds
that target G–RGS interactions can be found, ei-
ther by high-throughput screening90–92 or rational
design.93
An immediate target for intervention, with its dis-
tribution and ability to modulate both morphine-
induced and cocaine-induced behaviors, is RGS9-2.
On the basis of studies in rodents, a compound
that stimulates RGS9-2 levels or activity would be
expected to decrease stimulant and opioid reward
as well as dependence and drug-seeking behavior.
Conversely, in the pain clinic, where enhanced anal-
gesic activity of morphine is required, an inhibitor of
RGS9-2 activity would be the required target, pre-
dicted to enhance the antinociceptive response to
morphine and decrease acute tolerance. However,
because RGS9-2 appears to modulate all -opioid–
mediated behaviors, such an inhibitor would also
increase dependence, reward, and other unwanted
actions. An alternative approach might be to use an
RGS9-2 inhibitor as a adjunct to a partial agonist
(such as buprenorphine) where additional selectiv-
ity of action could be obtained based on efficacy.94,95
The small RGS proteins, such as RGS2 and RGS4,
are less likely targets. One RGS4-knockout mouse
strain shows no opioid phenotype, indicating that
there may be functional redundancy for GAP activ-
ity. Moreover, RGS2 and RGS4 are widely expressed
throughout the brain and thus much less likely to
provide a selective target, although it is possible
that selectivity could be imposed through specific
G subtype and receptor interactions. Furthermore,
RGS4 is important in the parasympathetic control
of heart rate,96 whereas RGS2 is important for blood
pressure regulation.97 Interference with these pro-
teins is likely to have serious cardiovascular effects.
Of the more than 30 RGS proteins identified, rel-
atively few have been studied in detail, yet several
have been reported to show changes in expression
in response to addictive drugs and may be impor-
tant in specific aspects of the pharmacology of ad-
diction. To study each RGS protein individually is
a daunting task. An alternative approach is to use
systems that express G proteins with a mutation in
the conserved RGS binding domain to render them
RGS insensitive.98 Such systems allow the study of
global RGS protein inhibition on receptor signal-
ing. Mice expressing these RGS-insensitive G pro-
teins are now available.99 Such mice will probably
show altered pharmacology across a whole spectrum
of effects but will at least provide proof of princi-
ple that the pharmacology of addictive drugs can
be profoundly altered by inhibition of RGS protein
GAP activity. We can look forward to learning much
more about the roles of these important accessory
proteins in the pharmacology of addiction and as
possible targets for addictive medications.
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